The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging
NCT05307627 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2024-08-06
Summary
This retrospective, observational study will assess the health status of short- and long-term low-dose naltrexone (LDN) users.
Conditions
- Aging
Interventions
- DRUG
-
low-dose naltrexone
LDN doses \<20 mg/day
Sponsors & Collaborators
-
AgelessRx
lead INDUSTRY
Principal Investigators
-
Sajad Zalzala, MD · AgelessRx
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-14
- Primary Completion
- 2023-12-14
- Completion
- 2023-12-14
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Pharmacokinetics of SP-104
NCT05002946 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
NCT04139824 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E
NCT00907400 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness of Theramine on Chronic Back Pain
NCT01468025 ·Status: COMPLETED ·Phase: PHASE3
-
Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances
NCT02272725 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E
NCT00761501 ·Status: COMPLETED ·Phase: PHASE1
-
PF-06372865 In Subjects With Chronic Low Back Pain
NCT02262754 ·Status: COMPLETED ·Phase: PHASE2
-
Naproxen Sodium Extended-Release Actual Use Study
NCT00751400 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations
NCT00692055 ·Status: COMPLETED ·Phase: PHASE1
-
Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study
NCT03167541 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations
NCT00665743 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Naproxen on Physical Performance
NCT00410995 ·Status: TERMINATED ·Phase: PHASE4
-
Safety Trial of Naproxen Sodium/ Diphenhydramine
NCT01365052 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Effect of Food on the Bioavailability of PN400 Components
NCT00676442 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
NCT05411718 ·Status: RECRUITING ·Phase: PHASE2
-
A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function
NCT00674856 ·Status: COMPLETED ·Phase: PHASE1
-
Anti-inflammatory Agents and Cholesterol Metabolism
NCT01279395 ·Status: TERMINATED
-
Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)
NCT00959439 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study PK Study With OXP005 and Naprosyn
NCT02351024 ·Status: COMPLETED ·Phase: PHASE1
-
Variability in Response to Non-steroidal Anti-inflammatory Drugs
NCT02502006 ·Status: TERMINATED ·Phase: PHASE1
-
Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male
NCT01404598 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal
NCT02169804 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Losartan on Cephalexin
NCT07300670 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects
NCT02108548 ·Status: TERMINATED ·Phase: PHASE1
-
Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions
NCT01052792 ·Status: COMPLETED ·Phase: PHASE1